ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced that its management will present at the HC Wainwright Ophthalmology Virtual Conference. The presentation will be available on demand starting August 17, 2021, at 7:00 am EDT. An archived version will be accessible for 30 days on the company’s website. ProQR is committed to developing transformative RNA therapies for genetic eye diseases, leveraging its proprietary RNA repair technologies.
- Company participation in HC Wainwright Ophthalmology Virtual Conference, enhancing visibility.
- Focus on transformative RNA therapies for severe genetic eye diseases could attract investor interest.
- None.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will present at the upcoming HC Wainwright Ophthalmology Virtual Conference. The presentation will be available on demand on August 17, 2021, at 7:00 am EDT.
An archived webcast of the presentation will be accessible from the “Investors & Media” section of ProQR’s website (www.proqr.com) under “Events” for approximately 30 days following the presentation date.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
Learn more about ProQR at www.proqr.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in this conference. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 430 7578
hans@lifesciadvisors.com
Media Contact:
Cherilyn Cecchini, MD
LifeSci Communications
T: +1 646 876 5196
ccecchini@lifescicomms.com
FAQ
When will ProQR's presentation at the HC Wainwright Ophthalmology Virtual Conference be available?
What is the focus of ProQR Therapeutics?
Where can I access the archived presentation of ProQR?
What is the stock symbol for ProQR Therapeutics?
